Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | PDE4A | P27815 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102010 | 0.80 | ALDH1A1 (0.45) | GSK3AGSK3BPDE4APDE4BPDE4C | |
| SCHEMBL957666 | 0.69 | — | — | |
| SCHEMBL12597287 | 0.67 | GSK3A (0.47) | GSK3AGSK3BPDE4APDE4BPDE4C | |
| SCHEMBL18462236 | 0.67 | DAO (0.48) | GSK3AGSK3BPDE4APDE4BPDE4C | |
| SCHEMBL3380286 | 0.64 | GSK3A (1.00) | GSK3AGSK3BL3MBTL1SIGMAR1MGLL | |
| SCHEMBL30371663 | 0.62 | TDP1 (0.86) | GSK3AGSK3BL3MBTL1ALDH1A1ALDH2 | |
| SCHEMBL40501 | 0.62 | GSK3A (0.65) | GSK3AGSK3BL3MBTL1SIGMAR1MGLL | |
| SCHEMBL45050 | 0.62 | TDP1 (0.86) | GSK3AGSK3BL3MBTL1ALDH1A1ALDH2 | |
| SCHEMBL1491103 | 0.62 | ALDH1A1 (0.49) | GSK3AGSK3BSIGMAR1ALDH1A1PKM | |
| SCHEMBL10494043 | 0.62 | SIGMAR1 (0.46) | GSK3AGSK3BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319349-A1 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events | SCOTT ROBERT A D (US) | 2011-12-29 | — | — | US | disclosed |
| EP-1931355-A2 | METHODS FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS | Atherogenics, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | CRABTREE ACQUISITION CO, LLC | 2007-09-13 | — | — | US | disclosed |
| WO-2007044726-A2 | METHODS FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS | ATHEROGENICS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1446113-A4 | COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION | ATHEROGENICS INC (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
| EP-1446113-A2 | COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION | Atherogenics, Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| US-5684029-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0468470-B1 | Benzimidazoles, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-04-16 | — | — | EP | disclosed |
| US-5614519-A | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists | KARL THOMAE GMBH (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5602127-A | ADMINISTERING TO TREAT HYPERTENSION | KARL THOMAE GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5587393-A | ANGIOTENSIN ANTAGONIST USEFUL IN TREATING HYPERTENSION | DR. KARL THOMAE GMBH (DE) | 1996-12-24 | — | — | US | disclosed |
| US-5385925-A | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1995-01-31 | — | — | US | disclosed |
| EP-0502314-A1 | Benzimidazol, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0468470-A1 | Benzimidazoles, medicaments containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | GSK3A 782/4885GSK3B 704/4885PDE4A 2614/4885 |
| US-20110319349-A1 | Methods for Reducing Platelet Activation and for the Treatment of Thrombotic Events | PLAT, F2, TFPI | GSK3A 2284/4885GSK3B 2369/4885PDE4A 594/4885 |
| US-20070213303-A1 | Methods for reducing platelet activation and for the treatment of thrombotic events | PLAT, F2, TFPI | GSK3A 2284/4885GSK3B 2369/4885PDE4A 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.